Robert Knight
Impact in
- Hematology top 0.02%
- Multiple Myeloma Research and Treatments
- Acute Myeloid Leukemia Research
- Oncology top 0.2%
- Bone health and treatments
- Peptidase Inhibition and Analysis
- Cancer Treatment and Pharmacology
Papers in
- Hematology 130
- Multiple Myeloma Research and Treatments 104
- Acute Myeloid Leukemia Research 37
-
- Protein Degradation and Inhibitors 32
- Developmental Biology and Gene Regulation 15
- Cancer therapeutics and mechanisms 14
- Co-authors
- Jerome B. Zeldis (56 shared papers)Zhinuan Yu (29 shared papers)Marta Olesnyckyj (34 shared papers)John J. Seaman (11 shared papers)Meletios Α. Dimopoulos (28 shared papers)Dirk J. Reitsma (6 shared papers)Joseph F. Simeone (5 shared papers)Allan Lipton (7 shared papers)
- Journals
- Blood (62 papers)Journal of Clinical Oncology (37 papers)Leukemia Research (8 papers)New England Journal of Medicine (6 papers)Development (5 papers)
- Partner nations
- United StatesUnited KingdomSwitzerland
In The Last Decade
Robert Knight
202 papers receiving 12.7k citations
Robert Knight's Hit Papers
Peers
Comparison fields: 5 of 146
- Hematology 7.9k
- Oncology 5.9k
- Genetics 1.7k
- Orthopedics and Sports Medicine 642
- Molecular Biology 5.6k
Countries citing papers authored by Robert Knight
This map shows the geographic impact of Robert Knight's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Knight with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Knight more than expected).
Fields of papers citing papers by Robert Knight
This network shows the impact of papers produced by Robert Knight. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Knight. The network helps show where Robert Knight may publish in the future.
Co-authors
The 25 scholars most cited alongside Robert Knight, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 206 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma Hit paper breakdown → | 2007 | 1106 |
| 2 | Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America Hit paper breakdown → | 2007 | 955 |
| 3 | Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion Hit paper breakdown → | 2006 | 938 |
| 4 | Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma Hit paper breakdown → | 1996 | 848 |
| 5 | Efficacy of Pamidronate in Reducing Skeletal Complications in Patients with Breast Cancer and Lytic Bone Metastases Hit paper breakdown → | 1996 | 833 |
| 6 | Efficacy of Lenalidomide in Myelodysplastic Syndromes Hit paper breakdown → | 2005 | 643 |
| 7 | Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. Hit paper breakdown → | 1998 | 512 |
| 8 | Pamidronate Reduces Skeletal Morbidity in Women With Advanced Breast Cancer and Lytic Bone Lesions: A Randomized, Placebo-Controlled Trial Hit paper breakdown → | 1999 | 504 |
| 9 | 1998 | 494 | |
| 10 | Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis Hit paper breakdown → | 2017 | 409 |
| 11 | 2007 | 323 | |
| 12 | 2009 | 280 | |
| 13 | 2008 | 266 | |
| 14 | 2004 | 242 | |
| 15 | 2007 | 222 | |
| 16 | 2007 | 205 | |
| 17 | 2003 | 171 | |
| 18 | 2008 | 136 | |
| 19 | 1998 | 133 | |
| 20 | 2009 | 131 |
About Robert Knight
Robert Knight is a scholar working on Hematology, Molecular Biology, Oncology, Genetics and Genetics, having authored 206 papers that have together received 13.3k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (104 papers), Cancer Treatment and Pharmacology (47 papers), Acute Myeloid Leukemia Research (37 papers), Protein Degradation and Inhibitors (32 papers), Chronic Lymphocytic Leukemia Research (20 papers), Developmental Biology and Gene Regulation (15 papers), Cancer therapeutics and mechanisms (14 papers) and Bone health and treatments (11 papers). The work is most often cited by research in Hematology (7.9k citations), Oncology (5.9k citations), Genetics (1.7k citations), Orthopedics and Sports Medicine (642 citations) and Molecular Biology (5.6k citations). Robert Knight has collaborated with scholars based in United States, United Kingdom and Switzerland. Frequent co-authors include Jerome B. Zeldis, Zhinuan Yu, Marta Olesnyckyj, John J. Seaman, Meletios Α. Dimopoulos, Dirk J. Reitsma, Joseph F. Simeone, Allan Lipton, John Patin and Alan F. List. Their work appears in journals such as Blood, Journal of Clinical Oncology, Leukemia Research, New England Journal of Medicine and Development.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.